Evolution of therapy decision-making process for advanced non-small cell lung cancer.
Advanced non-small cell lung cancer remains a lethal disease with poor prognosis. In the last decades results of systemic chemotherapy have reached a disappointing plateau without significant differences between the most widely employed third-generation regimens. Recent scientific evidence has shed new light on the management of advanced non-small cell lung cancer, especially for the important role of histological definition in therapy-planning process. The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment.
Gebbia
Vittorio
V
Department of Experimental Oncology and Medical Applications (DOSAC), University of Palermo, and Medical Oncology Division, La Maddalena Clinic for Cancer, Palermo, Italy. vittorio.gebbia@tin.it
Mancuso
Gianfranco
G
Lombardi
Lucia
L
Maiello
Evaristo
E
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D003657:Decision Making; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor